Zhitong Finance App News, BeiGene (688235.SH) announced that the company's product Baiyueda® (BEQALZI™) has obtained accelerated approval from the US Food and Drug Administration (FDA) to treat adult patients with recurrent or refractory (R/R) mantle cell lymphoma (MCL) who have previously received at least two line system treatments (including Bruton's tyrosine kinase (BTK) inhibitors).

Zhitong Finance App News, BeiGene (688235.SH) announced that the company's product Baiyueda® (BEQALZI™) has obtained accelerated approval from the US Food and Drug Administration (FDA) to treat adult patients with recurrent or refractory (R/R) mantle cell lymphoma (MCL) who have previously received at least two line system treatments (including Bruton's tyrosine kinase (BTK) inhibitors).